Wells Fargo & Company MN raised its position in Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) by 1,738.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 47,801 shares of the specialty pharmaceutical company’s stock after buying an additional 45,201 shares during the quarter. Wells Fargo & Company MN’s holdings in Foamix Pharmaceuticals were worth $265,000 at the end of the most recent reporting period.

Separately, Bank of New York Mellon Corp raised its stake in shares of Foamix Pharmaceuticals by 4.9% in the third quarter. Bank of New York Mellon Corp now owns 571,639 shares of the specialty pharmaceutical company’s stock valued at $3,172,000 after buying an additional 26,786 shares during the period. Institutional investors own 57.39% of the company’s stock.

Shares of Foamix Pharmaceuticals Ltd (NASDAQ FOMX) opened at $6.65 on Wednesday. Foamix Pharmaceuticals Ltd has a one year low of $4.03 and a one year high of $11.11.

Foamix Pharmaceuticals (NASDAQ:FOMX) last released its quarterly earnings data on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.03). Foamix Pharmaceuticals had a negative net margin of 1,439.32% and a negative return on equity of 54.81%. The company had revenue of $0.90 million for the quarter, compared to the consensus estimate of $0.90 million. During the same quarter in the previous year, the firm posted ($0.19) earnings per share. The business’s revenue for the quarter was down 64.6% compared to the same quarter last year. equities research analysts expect that Foamix Pharmaceuticals Ltd will post -1.75 EPS for the current year.

In related news, insider Meir Eini sold 5,000 shares of the business’s stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $6.68, for a total transaction of $33,400.00. Following the sale, the insider now directly owns 16,271 shares in the company, valued at approximately $108,690.28. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last quarter, insiders have sold 20,000 shares of company stock worth $125,400.

FOMX has been the topic of a number of analyst reports. HC Wainwright set a $12.00 price objective on Foamix Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, November 29th. Guggenheim initiated coverage on Foamix Pharmaceuticals in a research note on Tuesday, December 5th. They set a “buy” rating and a $8.00 price objective on the stock. Finally, Zacks Investment Research upgraded Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, November 29th.

ILLEGAL ACTIVITY WARNING: “Wells Fargo & Company MN Raises Holdings in Foamix Pharmaceuticals Ltd (FOMX)” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.watchlistnews.com/wells-fargo-company-mn-raises-holdings-in-foamix-pharmaceuticals-ltd-fomx/1850025.html.

Foamix Pharmaceuticals Company Profile

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.

Want to see what other hedge funds are holding FOMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX).

Institutional Ownership by Quarter for Foamix Pharmaceuticals (NASDAQ:FOMX)

Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.